A Metastatic Cervical Adenocarcinoma Patient Carrying HER2 G292R Achieved Complete Response Upon Pyrotinib Treatment

Figures & data

Figure 1 A summary of patient’s treatment history.

Abbreviations: PR, partial response; PD, progressive disease; SD, stable disease; CR, complete response; PFS, progression-free survival; NGS, next-generation sequencing; HER2, ERBB2 receptor tyrosine kinase 2; IMRT, intensity-modulated radiation therapy.

Figure 2 Magnetic resonance imaging (MRI) of the liver (upper) and cervical (lower) lesions at treatment milestones. (A) at baseline; (B) two weeks after IMRT directed to pelvis; (C) two months after IMRT directed to neck combined with brachytherapy and platinum-based chemotherapy (PR); (D) seven months after IMRT directed to neck combined with brachytherapy and platinum-based chemotherapy (PD). (E) three months after pyrotinib treatment (SD); (F) seventeen months after pyrotinib treatment (CR). The red arrows in upper and lower panels indicated metastatic live lesion and the primary cervical adenocarcinoma, respectively.

Abbreviations: PR, partial response; PD, progressive disease; SD, stable disease; CR, complete response; IMRT, intensity-modulated radiation therapy.

Figure 3 Hematoxylin & eosin (H&E)/immunohistochemistry (IHC) staining on the primary cervical adenocarcinoma/neck lymph node. (A) H&E staining on the primary cervical adenocarcinoma; (B) H&E staining on the neck lymph node; (C) IHC staining for HER2 on the primary cervical adenocarcinoma.

Abbreviations: H&E, hematoxylin & eosin; IHC, immunohistochemistry; HER2, ERBB2 receptor tyrosine kinase 2.